NRG-LU006: Testing the Addition of Targeted Radiotherapy to Surgery & the Usual Systemic Therapy for Malignant Pleural Mesothelioma

NRG-LU006 was a clinical trial studying whether adding targeted radiation therapy called IMPRINT to the usual treatment of surgery and systemic therapy with chemotherapy or immune therapy, can help to extend the life of people with malignant pleural mesothelioma (MPM). MPM is a tumor of the tissue that lines the surface of the lungs. Usual treatment includes a pleurectomy/decortication which is surgery to remove the malignant mesothelioma along with the pleura which is the lung lining followed by chemotherapy drugs. Recently, immune therapy has been approved to treat MPM and can be given before surgery either with chemotherapy or alone. Researchers want to know if IMPRINT, which is a technique that targets radiation treatment directly to the pleura, in addition to surgery and systemic therapy will be as good as or better than the usual treatment of the surgery plus systemic therapy alone (without IMPRINT).